For laboratory research use only - not for human consumption

Compound hub · Tirzepatide

What is tirzepatide? Questions answered from the trial record

Tirzepatide is a lab-made peptide, a short chain of amino acids, that switches on the receptors for two gut hormones, GIP and GLP-1. Tirzepatide is sold in Australia as the prescription medicine Mounjaro. In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity or overweight and no diabetes, average weight fell 15.0% to 20.9% on tirzepatide and 3.1% on placebo. Those are group averages, not one person's result.

Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.

Published 2026-10-14Updated 2026-10-16Written by Form Laboratories research team21 min read

Think of a key cut to open two different locks. Tirzepatide is one molecule built to fit two receptors at once. They are the ones for the gut hormones GLP-1 and GIP. The TGA's assessment report for Mounjaro names the pancreas, the gut and the brain among the places where GLP-1 acts. That double fit is why tirzepatide draws so many questions.

The questions below come from real search boxes. They ask what tirzepatide is, what it is called in Australia, what trials found, what the labels warn about, and what happens when treatment stops. This page is part of the tirzepatide hub. Each answer rests on a named study or regulator document. None of it is advice on use. The US labels used are on DailyMed: Mounjaro and Zepbound, both published 2 September 2026, and Ozempic, 10 June 2026. The Australian records are listed next. One is the Mounjaro Product Information published with that report (version dated August 2024; a later version may have replaced it). Others are the Ozempic assessment report (October 2020) and the TGA Medicines Safety Update of 3 June 2025. Others are the TGA's update of 18 June 2024 on compounding and the TGA register entry for Mounjaro (read 14 October 2026). The last is the PBS Medicine Status page for tirzepatide (current as at 1 October 2026).

Key facts

Key facts for What is tirzepatide? Questions answered from the trial record
Common nametirzepatide
Research codeLY3298176 (named in Coskun et al., 2018)
Structure39-amino-acid linear peptide with a C20 fatty diacid at position 20 (Coskun et al., 2018)
Receptors activatedGIP and GLP-1 (US Mounjaro label, published 2 September 2026)
Australian brand nameMounjaro (TGA register entry, read 14 October 2026)
US brand namesMounjaro (label); Zepbound (label); both published on DailyMed on 2 September 2026
First TGA register entry23 December 2022 (type 2 diabetes), per the TGA register entry
Weight-management indication (TGA)Decision date 9 September 2024; registered 10 September 2024 (TGA register entry)
Medicine schedule (Australia)Schedule 4, prescription only (Poisons Standard F2026L01327, read 14 October 2026)
Reported half-lifeAbout 5 days. This is a group estimate from human label data with no participant count given (US Mounjaro label, DailyMed, 2 September 2026).
Time to peak blood level8 to 72 hours. This is a group range from human label data with no participant count given (US Mounjaro label, DailyMed, 2 September 2026).
Obesity trial in the TGA submissionSURMOUNT-1, NCT04184622: 2,539 adults, 72 weeks, double-blind
PBS status as at 1 October 2026The PBS Medicine Status page records three things. The company is not proceeding with the listing process. The process has ceased. There is no PBS listing.
Facts checked14 October 2026 against the sources cited below
Coskun et al., Molecular Metabolism 2018MedlinePlus, tirzepatide entry, pronunciation guide; revised 15 February 2026; https://medlineplus.gov/druginfo/meds/a622044.html

What is tirzepatide, and how is its name pronounced?

Tirzepatide is a lab-made peptide. Its name is said tir-ZEP-a-tide, with the stress on ZEP. A peptide is a short chain of amino acids, the same building blocks that make up proteins. Tirzepatide switches on two receptors. A receptor is a protein on a cell that picks up one kind of signal, like a lock that opens for one key. These two receptors pick up signals from the gut hormones GIP and GLP-1. A molecule that switches a receptor on is called an agonist. So tirzepatide is a dual agonist. The name labels a molecule. It says nothing about anyone's health.

Molecular Metabolism 2018US Mounjaro label (DailyMed), 2 September 2026US Ozempic label (DailyMed), 10 June 2026TGA assessment report, Ozempic, October 2020

What is tirzepatide, and is it a peptide like Ozempic?

Yes, tirzepatide is a peptide, but it is a different molecule from the one in Ozempic. Tirzepatide is a chain of 39 amino acids with a fatty tail, a C20 fatty diacid, attached at position 20. The US Mounjaro label says it is based on the GIP sequence and switches on both the GIP and GLP-1 receptors. Ozempic's active ingredient is semaglutide. Semaglutide is a close copy of human GLP-1, with 94% sequence homology. This means 94% of its chain matches. It is made by yeast cells using recombinant DNA technology and then chemically modified. Both medicines contain peptides, but not the same peptide.

'Peptide' is the name of a chemical family: short chains of amino acids. The two labels share one design idea. Each molecule carries a fatty tail that lets it stick to albumin, the main carrier protein in blood. The Mounjaro label says this makes the half-life longer. The Ozempic label says albumin binding is the main reason semaglutide lasts. The two differ in the receptors they switch on. These are set out side by side in tirzepatide vs semaglutide.

Where tirzepatide comes from traces the molecule from its 2018 discovery paper to its registered form.

Diagram of one key-shaped molecule fitting two different lock-shaped receptors on a cell surface. Labels read One molecule, GIP receptor and GLP-1 receptor.
Tirzepatide is one molecule that switches on two receptors, the GIP receptor and the GLP-1 receptor, like one key that fits two locks (Coskun et al., Molecular Metabolism, 2018; US Mounjaro label, DailyMed, 2 September 2026).
TGA assessment report, Mounjaro, 20 September 2024TGA register entries for Mounjaro, read 14 October 2026TGA Medicines Safety Update, 3 June 2025TGA update on GLP-1 compounding, 18 June 2024US Mounjaro and Zepbound labels (DailyMed), 2 September 2026

Is tirzepatide the same as Mounjaro, and what is it called in Australia?

Yes. Tirzepatide is the generic name of the molecule, and Mounjaro is its brand name in Australia. The TGA register entry shows Mounjaro registered on 23 December 2022 for type 2 diabetes. A weight-management entry followed, with a decision on 9 September 2024 and registration on 10 September 2024. An entry dated 2 June 2025 adds obstructive sleep apnoea, where breathing keeps stopping during sleep. In June 2025 the TGA listed Mounjaro as the dual GIP/GLP-1 agonist marketed in Australia. In the United States, the same molecule has two brand names. They are Mounjaro, and Zepbound, whose label covers weight reduction and obstructive sleep apnoea.

'Types' of tirzepatide are really types of product. The Product Information published with the 2024 assessment report lists vials and pre-filled pens, including a KwikPen. Compounded copies are a separate group. Compounding means a pharmacist makes up a medicine themselves. The TGA's update of 18 June 2024 records that changes to the Therapeutic Goods Regulations 1990 stop pharmacists compounding medicines containing GLP-1 receptor agonist analogues on or after 1 October 2024. They also stop pharmacists supplying such medicines to patients. The TGA also notes that compounded products are not identical to TGA-approved products.

Is Mounjaro 'stronger' than the tirzepatide compound? They share a molecule, so the word fits neither. What differs is that the registered product has a TGA register entry and Product Information. Research-use tirzepatide is listed in the catalogue as tirzepatide reference material. It is a laboratory compound. It is not a medicine. It is not a substitute for one. It is not for human or animal use.

US Mounjaro label (DailyMed), 2 September 2026Mounjaro Product Information, version dated August 2024SURMOUNT-1, NEJM 2022

What does the label record happening in the body with tirzepatide, and what did trials record early on?

The Mounjaro label lists four changes measured in people with type 2 diabetes. Blood sugar was lower before and after meals. People ate less food. There was less glucagon, a hormone that raises blood sugar. And gastric emptying slowed, meaning the stomach emptied more slowly. The label gives no participant count for these summaries. They do not predict how any one person responds. The Australian Product Information says blood levels peaked 8 to 72 hours after study exposure, again with no participant count. SURMOUNT-1 was a trial funded by the maker, with 2,539 adults with obesity or overweight and no diabetes. The most common side effects were in the gut and mostly mild to moderate.

Both receptors are found in many parts of the body. The Australian Product Information lists the pancreas (its alpha and beta cells), brain, heart, blood vessels, immune cells, gut and kidney for both receptors. It lists fat cells for the GIP receptor. That list says where the receptors sit. It is not a measured effect.

The US label also describes a marker test for stomach emptying, using paracetamol. How fast it shows up in the blood reflects how fast the stomach empties. At the first study check, the peak paracetamol level was 50% lower and arrived one hour later. The label summary does not say who was studied or how many. A marker is a lab reading, not what any person feels.

SURMOUNT-1, NEJM 2022SURPASS-2, NEJM 2021SURMOUNT-4, JAMA 2024ClinicalTrials.gov NCT04184622

What is the success rate of tirzepatide? What SURMOUNT-1 found

Tirzepatide has no single success rate, because each trial measures something different. The best-known figure comes from SURMOUNT-1. This was a 72-week trial of 2,539 adults with obesity or overweight and a weight-related condition, but no diabetes. People were placed by chance into one of three tirzepatide groups or a placebo group. Neither they nor the staff knew which. Average weight fell 15.0%, 19.5% and 20.9% in the tirzepatide groups and 3.1% on placebo. These averages counted everyone, including people who stopped treatment. The maker funded the trial. A group average cannot predict one person's result.

Another way to read SURMOUNT-1 is by how many people reached a target. At least 5% of body weight was lost by 85%, 89% and 91% of the three tirzepatide groups, against 35% on placebo. At least 20% was lost by 50% and 57% of the two higher groups, against 3% on placebo. Side effects made 4.3%, 7.1% and 6.2% of the tirzepatide groups stop treatment, against 2.6% on placebo. SURMOUNT-1 did not include people with type 2 diabetes, so it cannot speak for them.

The SURPASS trials do include people with type 2 diabetes. SURPASS-2 was an open-label trial, so everyone knew which drug they had. It had 1,879 adults with type 2 diabetes, and the maker funded it. At 40 weeks, average HbA1c fell 2.01 to 2.30 percentage points on tirzepatide and 1.86 on semaglutide. HbA1c is a blood test that reflects average blood sugar over about three months.

SURMOUNT-4 asked what happens when treatment continues or stops. Its 670 adults, with obesity or overweight and no diabetes, had first completed 36 weeks of open-label tirzepatide. They were then split by chance to keep going or switch to placebo. From week 36 to week 88, weight changed by −5.5% on tirzepatide and +14.0% on placebo. Only people who finished the first phase took part. So the result does not describe all adults with obesity. How the SURPASS and SURMOUNT trials differ explains each end point.

US Mounjaro label (DailyMed), 2 September 2026US Ozempic label (DailyMed), 10 June 2026Mounjaro Product Information, version dated August 2024

Does Mounjaro wear off after five days? What the half-life means

Not in the sense of being gone. Five days is the half-life, the time it takes for the amount in the blood to fall by half. It is not the time until the drug has cleared. The Mounjaro label gives tirzepatide a half-life of about 5 days. After one half-life about half is left, and after two about a quarter. The label also says about 80% of the drug reaches the bloodstream. This measure is called bioavailability. Both numbers are group estimates from human studies, with no participant count given. They are not measurements for one person.

The body breaks the molecule down with its own tools. The label describes three steps. Enzymes cut the peptide chain (proteolytic cleavage). The fatty tail is broken down (beta-oxidation). Amide bonds are split (amide hydrolysis). The leftover pieces leave mainly in urine and faeces. For comparison, the Ozempic label gives semaglutide a half-life of about 1 week. It estimates semaglutide stays in circulation for about 5 weeks after the final study exposure. Those are also group estimates with no participant count.

US Zepbound label (DailyMed), 2 September 2026SURMOUNT-1, NEJM 2022SURPASS-2, NEJM 2021Diabetes, Obesity and Metabolism 2025

What is the bad side of tirzepatide? Adverse events recorded in the trials

The most common problems in trials were in the gut. The US Zepbound label pools two placebo-controlled weight trials: 2,519 adults on tirzepatide and 958 on placebo, all with obesity or overweight, some with type 2 diabetes. Nausea affected 25% to 29% on tirzepatide against 8% on placebo. Diarrhoea affected 19% to 23% against 8%, vomiting 8% to 13% against 2%, and constipation 11% to 17% against 5%. Side effects made 4.8% to 6.7% stop for good, against 3.4% on placebo. Most who stopped did so in the first few months, because of gut problems. These are group rates, not predictions for one person.

An adverse event is any health problem recorded during a trial, whether or not the drug caused it. The table below sets ten of the label's 16 listed reactions beside placebo. In the same pool, hair loss was recorded in 4% to 5% against 1%. Tiredness (fatigue) was recorded in 5% to 7% against 3%. SURMOUNT-1 was funded by the maker and had 2,539 adults with obesity or overweight and no diabetes. It also found gut problems were the most common, and mostly mild to moderate. SURPASS-2 was an open-label trial of 1,879 adults with type 2 diabetes. In it, serious adverse events were 5% to 7% on tirzepatide and 3% on semaglutide.

Trials also looked at what kind of weight is lost. A body-scan substudy of SURMOUNT-1 was selected. It had 160 adults with obesity or overweight and no diabetes (124 on tirzepatide, 36 on placebo). About a quarter of the weight lost was lean mass, meaning tissue other than fat, in both groups. That is a group figure, not anyone's body. The tirzepatide vs semaglutide page covers how that compares.

US Mounjaro and Ozempic labels (DailyMed), 2 September 2026 and 10 June 2026Mounjaro Product Information, version dated August 2024TGA Medicines Safety Update, 3 June 2025

What organ is tirzepatide or Ozempic hard on? What the labels warn about

The labels name organs in their warnings. But a search of their text on 14 October 2026 found none calling a medicine 'hard on' an organ. The US Mounjaro label and the US Ozempic label both warn about acute pancreatitis (an inflamed pancreas). Both warn about acute gallbladder disease, which the Mounjaro label says occurred in trials. Both warn about sudden kidney injury from losing too much fluid. The Australian Product Information says gut side effects can cause dehydration that could worsen kidney function, including acute renal failure. The Mounjaro label's boxed warning says tirzepatide caused thyroid C-cell tumours in rats. It gives no animal count. Whether this happens in humans is unknown.

Other warnings involve the eyes, the stomach and the lungs. In the eyes, fast drops in blood sugar are linked to a temporary worsening of diabetic retinopathy. This is damage to the back of the eye caused by diabetes. In the stomach, there are warnings for slow emptying and severe gut reactions. In the lungs, there are reports of pulmonary aspiration, meaning stomach contents entering the lungs, in people under general anaesthesia or deep sedation. In June 2025 the TGA reported a class-wide warning about this being added to the Product Information and Consumer Medicine Information of these medicines.

The Australian Product Information also notes that tirzepatide has not been studied in people who have had pancreatitis. A warning records what a label says. It is not a finding about any one person's risk.

Mounjaro Product Information, version dated August 2024US Mounjaro label (DailyMed), 2 September 2026TGA assessment report, Mounjaro, 20 September 2024

What do the labels list as contraindications for tirzepatide?

The Australian Product Information lists one contraindication. This is a reason a medicine must not be used. It is known hypersensitivity, an allergy-type reaction, to tirzepatide or any ingredient in Mounjaro. The US label adds a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer. It also adds a history of multiple endocrine neoplasia syndrome type 2 (MEN 2), an inherited condition that causes tumours in hormone glands. The TGA gives Mounjaro pregnancy category D. The TGA defines that category as 'drugs which have caused, are suspected to have caused or may be expected to cause an increased incidence of human fetal malformations or irreversible damage'.

Australia and the United States word these sections differently, and both documents change over time. The Australian document says safety and efficacy (how well it works) in people under 18 have not been established. The US Mounjaro label lists type 2 diabetes in children aged 10 years and over.

STEP 1, NEJM 2021Journal of Diabetes 2026JAMA Internal Medicine 2024Diabetes, Obesity and Metabolism 2022SURMOUNT-4, JAMA 2024

Why are people stopping Wegovy and other GLP-1 medicines, and what happens when treatment stops?

Studies count how often people stop and what happens next. But the PubMed and ClinicalTrials.gov searches for this page on 14 October 2026 found no single reason why. STEP 1 was a double-blind trial of 1,961 adults with overweight or obesity and no diabetes, funded by the maker of semaglutide. In it, gut side effects made 4.5% on semaglutide stop, against 0.8% on placebo. A US study followed 18,386 matched adults with overweight or obesity given tirzepatide or semaglutide in forms labelled for type 2 diabetes. Follow-up ended because the person stopped in 52.5% on semaglutide and 55.9% on tirzepatide. That study only watched what happened, so it cannot show cause.

What happens after stopping is better measured. The STEP 1 extension was an exploratory follow-up of 327 adults with overweight or obesity and no diabetes. People who had taken semaglutide regained 11.6 percentage points of the weight they had lost within one year of stopping. That is about two-thirds of the earlier loss. In SURMOUNT-4, 670 adults who had finished 36 weeks of tirzepatide were split by chance to keep going or switch to placebo. On placebo, weight rose 14.0% from week 36 to 88, and 16.6% kept at least 80% of their loss. Of those who stayed on tirzepatide, 89.5% did. Only people who finished the first phase took part.

These are group results. The maker of semaglutide funded STEP 1. The abstracts of SURMOUNT-4 and the STEP 1 extension name no funder. None of them explains why one person stops. And 'tolerability' is only a label unless a paper measured it.

JAMA Internal Medicine 2024

Why do some people say they feel so good on semaglutide or GLP-1 medicines?

No published study explains why some people say they feel good. The PubMed and ClinicalTrials.gov searches for this page on 14 October 2026 found none. What trials did measure is depression scores. One analysis looked back, after the fact, at four double-blind semaglutide trials (STEP 1, 2, 3 and 5) in people without known major mental illness. In STEP 1 to 3, 3,377 adults with overweight or obesity started with scores showing no or minimal depression. At week 68, the PHQ-9 depression questionnaire averaged 2.0 on semaglutide and 2.4 on placebo, a difference of −0.56 (95% CI −0.81 to −0.32). The authors call that small and not clinically meaningful.

That analysis was written to check psychiatric safety. It cannot say that anyone's mood changed because of the drug. The 95% CI, or confidence interval, is the range in which the true difference probably lies.

Reports of feeling well, without a comparison group, cannot show that a medicine caused the change. They may reflect weight change, blood-sugar change or something else. The searches for this page found no trial that tested which.

SURPASS-2, NEJM 2021SURMOUNT-5, NEJM 2025Retatrutide Phase 2, NEJM 2023REDEFINE 1, NEJM 2025

Is tirzepatide stronger than Ozempic, and what medicine is stronger than tirzepatide?

'Stronger' is not something these trials measured. They measured specific results. SURPASS-2 was an open-label trial of 1,879 adults with type 2 diabetes, funded by the maker. Average HbA1c fell 2.01 to 2.30 percentage points on tirzepatide and 1.86 on semaglutide. SURMOUNT-5 was a 72-week open-label trial of 751 adults with obesity, also funded by the maker. Average weight changed −20.2% on tirzepatide against −13.7% on semaglutide. The searches for this page on 14 October 2026 found no head-to-head trial showing larger average changes on a registered medicine than on tirzepatide. Retatrutide has a separate trial record, not a proven ranking against tirzepatide.

The retatrutide Phase 2 trial was double-blind and funded by the maker. 338 adults with obesity or overweight and a weight-related condition took part for 48 weeks. Average weight in the higher retatrutide group changed −24.2%, against −2.1% on placebo. That is a group result. It cannot rank retatrutide against tirzepatide. REDEFINE 1 was a 68-week double-blind trial of 3,417 adults with obesity or overweight and no diabetes, funded by the maker of semaglutide. Average weight changed −20.4% on a cagrilintide–semaglutide combination against −3.0% on placebo. That is a different trial population, not a direct comparison with tirzepatide. The full comparison and the retatrutide comparison page set them out.

TGA Medicines Safety Update, 3 June 2025TGA assessment report, Mounjaro, 20 September 2024TGA register entries for Ozempic and Wegovy, read 14 October 2026

Which other GLP-1 medicines are registered in Australia?

In June 2025 the TGA listed the GLP-1 medicines then marketed in Australia: Ozempic and Wegovy (semaglutide), Trulicity (dulaglutide), and Victoza and Saxenda (liraglutide). Mounjaro was listed as the dual GIP/GLP-1 agonist. Ozempic, Trulicity and Victoza were approved for adults with type 2 diabetes. Saxenda and Wegovy were approved for long-term weight management. Other TGA register entries add uses for Ozempic (18 August 2025) and Wegovy (26 February 2024, 19 December 2024 and 30 March 2026), read 14 October 2026. The Mounjaro assessment report records that liraglutide was first registered in 2010, dulaglutide in 2015 and semaglutide in 2019.

This page lists neighbours by how they work and does not rank them. Tirzepatide vs semaglutide sets out what two head-to-head trials found for the nearest comparison.

The Lancet Diabetes & Endocrinology 2022US Mounjaro label (DailyMed), 2 September 2026

What have studies found about tirzepatide and insulin resistance?

One small early study measured how well the body makes and responds to insulin in adults with type 2 diabetes. Insulin resistance means cells respond weakly to insulin. This Phase 1 trial in Germany split 117 adults with type 2 diabetes on metformin by chance. 45 had tirzepatide, 44 had semaglutide and 28 had placebo. The 28-week analysis covered 102 of them. Tirzepatide raised the clamp disposition index by 1.92 more than placebo (95% CI 1.59 to 2.24) and 0.84 more than semaglutide (95% CI 0.46 to 1.21). This index is a score that combines insulin release and insulin sensitivity. The maker of tirzepatide funded the study.

The difference from semaglutide came from higher total insulin release and better insulin sensitivity. Both are lab measures, not long-term health outcomes. The study was double-blind and run at two centres. The 28-week analysis covered 39, 39 and 24 people in the three groups. The semaglutide group had 44 people in the safety count and 39 in the analysis. The result does not cover people who have insulin resistance but no diabetes.

The Lancet 2026Brain and Behavior 2026

What does research show about tirzepatide and dementia?

No randomised trial of tirzepatide for dementia turned up in the PubMed and ClinicalTrials.gov searches for this page on 14 October 2026. The nearest trials tested a different molecule, semaglutide. In evoke and evoke+, two double-blind phase 3 trials, 3,808 adults with early Alzheimer's disease took oral semaglutide or placebo. At week 104, the average change in a dementia rating score (the Clinical Dementia Rating Sum of Boxes) was 2.3 and 2.2 on semaglutide against 2.3 and 2.1 on placebo. Both trials were stopped because of a negative clinical outcome. A 2026 review of tirzepatide in brain and nerve disease found 22 studies. Of these, 11 were preclinical, three looked back at records, and eight were case reports.

The maker of semaglutide funded the evoke trials. They enrolled people who already had Alzheimer's disease, so they say nothing direct about tirzepatide. The 2026 review searched studies up to 30 September 2025. Its 11 preclinical studies were lab or animal work. Studies that look back at records (retrospective cohorts) can show links but not cause. Case reports have no comparison group. A hypothesis is a question to test, not a measured clinical result.

PBS Medicine Status page, tirzepatide, 1 October 2026TGA Medicines Safety Update, 3 June 2025TGA register entry for Ozempic, read 14 October 2026

Is Mounjaro listed on the PBS, and what is Ozempic's status in Australia?

No. The PBS Medicine Status page for tirzepatide, current at 1 October 2026, records no listing on the Pharmaceutical Benefits Scheme (PBS), the government scheme that subsidises medicines. It records that the company advised it is not going ahead with listing at this time, and that the process has ceased. The same page records that the Pharmaceutical Benefits Advisory Committee (PBAC) recommended listing for adults with poorly controlled type 2 diabetes at its 11 March 2026 meeting. Ozempic is a registered prescription medicine, first entered on the register on 28 August 2019. In June 2025 the TGA said Trulicity and Ozempic are available on the PBS (authority streamlined).

Against 'Medicine listed on the PBS', the page gives 'Not applicable'. The PBAC had considered tirzepatide in July 2023 (not recommended), November 2024 (not recommended) and July 2025 (deferred) before the March 2026 recommendation. This page reports status. It does not discuss prices or where to obtain a product. The Australian law hub covers how the Poisons Standard treats research peptides.

Comparison

Adverse reactions at 2% or more and greater than placebo in the two pooled placebo-controlled weight-reduction trials in the US Zepbound label (DailyMed, 2 September 2026). The people were adults with obesity or overweight. The lower tirzepatide arm had no participants with type 2 diabetes. The other groups included people with and without it. Placebo N=958; lower tirzepatide arm N=630; middle arm N=948; higher arm N=941. Each cell is the percentage of that group. These are group rates from trial participants. They are not predictions for any one person, not a comparison between medicines and not advice.

Comparison: What is tirzepatide? Questions answered from the trial record
Adverse reactionPlaceboLower tirzepatide armMiddle armHigher arm
Nausea8%25%29%28%
Diarrhoea8%19%21%23%
Vomiting2%8%11%13%
Constipation5%17%14%11%
Abdominal pain5%9%9%10%
Dyspepsia (indigestion)4%9%9%10%
Eructation (belching)1%4%5%5%
Flatulence2%3%3%4%
Hair loss1%5%4%5%
Fatigue3%5%6%7%

FAQ

How do you pronounce tirzepatide?

Tirzepatide is said tir-ZEP-a-tide. MedlinePlus writes it as 'tir zep' a tide', with the stress on ZEP (revised 15 February 2026). Tirzepatide is the molecule's name. Mounjaro is a brand name.

Who manufactures tirzepatide?

The records name a sponsor and a marketer. These are paperwork roles, not proof of where it is made. The Australian sponsor is Eli Lilly Australia Pty Ltd (TGA register, read 14 October 2026). The US marketer is Lilly USA, LLC (Mounjaro label, DailyMed, 2 September 2026). The label and Product Information sections searched on 14 October 2026 did not name manufacturing sites.

Is tirzepatide found in Ozempic?

No. Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 (US Ozempic label, DailyMed, 10 June 2026). Tirzepatide is the active ingredient in Mounjaro. The two molecules differ in structure and in the receptors they switch on (US Mounjaro label, DailyMed, 2 September 2026).

How long has Ozempic been around?

The US Ozempic label gives 2017 as the first US approval of semaglutide, the active ingredient. That field alone does not give the brand's own first approval date (DailyMed, 10 June 2026). In Australia, the TGA records a decision on 15 August 2019 and an entry on the register on 28 August 2019 (TGA assessment report for Ozempic, October 2020).

Can you smell when someone is on Ozempic?

No study that measured it turned up in the PubMed and ClinicalTrials.gov searches on 14 October 2026. The Ozempic and Zepbound US labels list belching and flatulence among side effects. A text search on 14 October 2026 of the Ozempic, Mounjaro and Zepbound US labels for 'odor', 'odour' and 'smell' found nothing (DailyMed, 2026). None of the trials cited here reports an 'Ozempic smell'.

Did trials record gas-related events with Zepbound?

Yes. The US Zepbound label's pool of two placebo-controlled weight trials had 2,519 adults on tirzepatide and 958 on placebo, with obesity or overweight, with and without type 2 diabetes. Flatulence occurred in 3% to 4% on tirzepatide against 2% on placebo. Abdominal pain occurred in 9% to 10% against 5%. Abdominal distension (bloating) occurred in 3% to 4% against 2%. These are group figures, not one person's experience (DailyMed, 2 September 2026).

What have GLP-1 medicine studies reported about adverse events, weight regain and lean mass?

SURMOUNT-1 had 2,539 adults with obesity or overweight and no diabetes, and the maker funded it. The most common side effects of tirzepatide were in the gut, mostly mild to moderate (Jastreboff et al., NEJM, 2022). In the exploratory STEP 1 extension of 327 adults with overweight or obesity and no diabetes, people who had taken semaglutide regained part of their lost weight in the year after stopping (Wilding et al., Diabetes, Obesity and Metabolism, 2022). In a selected 160-person SURMOUNT-1 body-scan substudy, about 25% of the weight lost was lean mass on both tirzepatide and placebo (Look et al., Diabetes, Obesity and Metabolism, 2025). These are group findings, not predictions and not advice.

Citations

16 sources
  1. Jastreboff AM et al. New England Journal of Medicine. 2022;387(3):205-216.
    doi:10.1056/NEJMoa2206038

  2. Coskun T et al. Molecular Metabolism. 2018;18:3-14.
    doi:10.1016/j.molmet.2018.09.009

  3. Frías JP et al. New England Journal of Medicine. 2021;385(6):503-515.
    doi:10.1056/NEJMoa2107519

  4. Aronne LJ et al. JAMA. 2024;331(1):38-48.
    doi:10.1001/jama.2023.24945

  5. Aronne LJ et al. New England Journal of Medicine. 2025;393(1):26-36.
    doi:10.1056/NEJMoa2416394

  6. Wilding JPH et al. New England Journal of Medicine. 2021;384(11):989-1002.
    doi:10.1056/NEJMoa2032183

  7. Wilding JPH et al. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
    doi:10.1111/dom.14725

  8. Rodriguez PJ et al. JAMA Internal Medicine. 2024;184(9):1056-1064.
    doi:10.1001/jamainternmed.2024.2525

  9. Bloomgarden Z Journal of Diabetes. 2026;18(7):e70248.
    doi:10.1111/1753-0407.70248

  10. Wadden TA et al. JAMA Internal Medicine. 2024;184(11):1290-1300.
    doi:10.1001/jamainternmed.2024.4346

  11. Look M et al. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729.
    doi:10.1111/dom.16275

  12. Heise T et al. The Lancet Diabetes & Endocrinology. 2022;10(6):418-429.
    doi:10.1016/S2213-8587(22)00085-7

  13. Cummings JL et al. The Lancet. 2026;407(10544):2167-2179.
    doi:10.1016/S0140-6736(26)00459-9

  14. Hawas Y et al. Brain and Behavior. 2026;16(8):e71702.
    doi:10.1002/brb3.71702

  15. Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972

  16. Garvey WT et al. New England Journal of Medicine. 2025;393(7):635-647.
    doi:10.1056/NEJMoa2502081

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

Tirzepatide reference material

Research use only, not for human or animal use.

Read the tirzepatide research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease